Delivery Order SPE2DB22D2214-SPE2DB25FS6LS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,909.80 to AmerisourceBergen Drug Corp for Linzess 72 microgram capsules (30-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed-price delivery order for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $8,164.40 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on September 19, 2025, with completion scheduled for September 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Linzess 290 microgram capsules (30-count units) at a ceiling value of $1,548.94. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion by August 18, 2025, with performance taking place at the vendor's facility in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a $11,335.78 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Linzess 290 microgram capsules in quantities of 30 units. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement with a completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Linzess 145 mcg capsules (30-count units) with a ceiling value of $4,586.15. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The order is due for completion by September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,423.44 to supply Linzess 72 microgram capsules (30-count units) under a firm fixed price contract. The award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a non-competitive, non-set-aside delivery order. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,064.49 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,247.40 to AmerisourceBergen Drug Corp for Linzess 145 microgram capsules (30-count units) under a firm fixed-price contract. The award was made on September 16, 2025, with an ultimate completion date of September 17, 2025. This non-set-aside contract represents a competitive award to the prime contractor, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $1,678.18 delivery order to AmerisourceBergen Drug Corp for LINZESS 145 microgram capsules (30-count units) on August 12, 2025, with completion targeted for August 13, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the awardee's facility in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Linzess 145 microgram capsules (30-count units) valued at $9,140.32. This is a firm fixed-price, competitive delivery order with no set-aside designation and an ultimate completion date of September 15, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS6LSDelivery Order
The Defense Logistics Agency awarded a $3,410.04 delivery order to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count unit of use packaging) with an ultimate completion date of September 8, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract vehicle with the federal government for pharmaceutical supply. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medications, medical devices, and healthcare commodities to support military and federal healthcare systems worldwide. The Linzess delivery represents the company's ongoing role in providing specialty pharmaceuticals across multiple therapeutic domains to the Defense Health Agency and other government healthcare customers through the DLA's flexible contract framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 9/6/25 |